1515
Annons
The exercise of Emplicure shares with the support of warrants of series TO1 begins today

Today, April 29 2022, the subscription period for warrants of series TO1 in Emplicure AB (publ) ("Emplicure" or "the Company") begins. The subscription period runs up to and including 13 May 2022. Each warrant of series TO1 entitles the holder to subscribe for one (1) new share in the Company at a price of SEK 2.09 per share. In order for the warrants not to expire without value, it is required that the holder actively subscribes for shares no later than 13 May 2022, or alternatively sells the warrants no later than 11 May 2022.

THE EXERCISE OF EMPLICURE SHARES WITH THE SUPPORT OF WARRANTS OF SERIES TO1 BEGINS TODAY

Today, April 29 2022, the subscription period for warrants of series TO1 in Emplicure AB (publ) ("Emplicure" or "the Company") begins. The subscription period runs up to and including 13 May 2022. Each warrant of series TO1 entitles the holder to subscribe for one (1) new share in the Company at a price of SEK 2.09 per share. In order for the warrants not to expire without value, it is required that the holder actively subscribes for shares no later than 13 May 2022, or alternatively sells the warrants no later than 11 May 2022.

The letter to warrant holders of series TO1 is attached in this press release and is also available on the Company's website at www.emplicure.com.

Complete terms and conditions for the warrants and application form are also available at the website address above.

Summarized terms for the warrants of series TO1:

Exercise period: From 29 April 2022 up to and including 13 May 2022.

Subscription price: SEK 2.09 per share.

Volume: 9,600,000 warrants of series TO1. If all the warrants of series TO1 are exercised, the number of shares in the Company will increase with 9,600,00 shares, and the Company will receive approximately SEK 20.1 million before issuing costs.

Last day for trading with warrants pf series TO1: 11 May 2022.

Share capital and dilution: If all the warrants are exercised the share capital will increase with SEK 480,000 from SEK 1,027,900 SEK to SEK 1,507,900 SEK. The number of shares will increase with 9,600,000 shares from 20,558,000 shares to 30,158,000 shares. If all the warrants are exercised the dilution will amount to approximately 31.8 percent of the number of shares and votes.

Note that warrants that are not exercised on 13 May 2022 at the latest will expire without value. To ensure that your warrants of series TO1 do not expire without value, you must actively subscribe for shares no later than 13 May 2022 or sell your warrants no later than 11 May 2022.  

How the warrants are exercised:

Nominee-registered Warrants (Custody account)         
Subscription and payment for shares subscribed for through exercising of Warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information.                

Direct-registered Warrants (Securities account)           
No accounts for issuing nor any instructions regarding payments will be sent out. Subscription shall be made through simultaneous payment in accordance with the instructions on the application form. The Warrants will then be replaced by interim shares awaiting registration at the Swedish Companies Registration Office.

Application form including payment instructions will be made available at the Company's website, www.emplicure.com and on Mangold Fondkommission AB's website www.mangold.se.

Advisors
Mangold Fondkommission AB is the financial advisor and issuing agent and Advokatfirman Lindahl KB is the legal advisor to Emplicure in connection with the exercise of the warrants.

For further information, please contact:

Torbjörn W. Larsson
CEO
Phone: +46 (0)70 747 65 99
Email: torbjorn.walkerlarsson@emplicure.com

Erik Magnusson
CFO, Investor Relations
Phone: +46 (0)708 565 245
Email: erik.magnusson@emplicure.com

Certified Adviser
Emplicure AB (publ) is listed on the Nasdaq First North Growth Market. Certified Adviser is Mangold Fondkommission AB, +46 8 503 015 50, or via ca@mangold.se

The following documents can be retrieved from beQuoted
PM-First-day-for-subscribtion-Emplicure-mark-up-2022-04-28.pdf
Brev-till-teckningsoptionsinnehavare-TO1.pdf

Emplicure is a pharmaceutical company developing new and innovative drugs by combining existing and approved active substances, and advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain, and with abuse deterrent formulations. The wholly owned subsidiary, Amplicon AB develops consumer products, with white oral nicotine as the first product. Read more at www.emplicure.com

Source: beQuoted
Tillbaka

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

spara
1090kr
Prenumerera